dabigatran
Term · Oncology and biomedicine · MLC-T-ONC-012891
A benzimidazole and direct thrombin inhibitor, with anticoagulant activity. Upon administration, dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.
| Identifier | MLC-T-ONC-012891 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012891",
"term": "dabigatran",
"field": "Oncology and biomedicine",
"definition": "A benzimidazole and direct thrombin inhibitor, with anticoagulant activity. Upon administration, dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dabigatran/"
}
Record 5,642 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.